Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on May 1, 2024, the Compensation Committee of Vera's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 15,000 shares of Class A common stock and restricted stock units (RSUs) for 7,500 shares of Class A common stock to three new employees under Vera's 2024 Inducement Plan (the Inducement Plan). Vera also announced that on May 6, 2024, the Compensation Committee granted additional inducement awards consisting of a non-qualified stock option to purchase 1,050 shares of Class A common stock and restricted stock units (RSUs) for 525 shares of Class A common stock to one new employee under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).
加利福尼亞州布里斯班，2024 年 5 月 7 日（GLOBE NEWSWIRE）—— Vera Therapeutics, Inc.（納斯達克股票代碼：VERA）今天宣佈，根據 Vera 的 2024 年激勵計劃，Vera 董事會薪酬委員會向三名新員工發放了由非合格股票期權組成的激勵性獎勵，用於以 7,500 股 A 類普通股購買 15,000 股 A 類普通股和限制性股票單位 (RSU) (激勵計劃).維拉還宣佈，2024年5月6日，薪酬委員會根據激勵計劃向一名新員工發放了額外的激勵性獎勵，包括以525股A類普通股購買1,050股A類普通股和限制性股票單位（RSU）的合格股票期權。根據納斯達克上市規則5635（c）（4），薪酬委員會批准將這些獎勵作爲新員工就業的激勵材料。
Each stock option granted on May 1, 2024 has an exercise price per share equal to $42.32 per share, Vera's closing trading price on May 1, 2024. the stock option granted on May 7, 2024 has an exercise price per share equal to $45.00 per share, Vera's closing trading price on May 7, 2024. Each stock option will vest over four years, with 25% of the underlying shares vesting on the first anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employee's continued service relationship with Vera through the applicable vesting dates. Each of the RSUs will vest over four years, with 25% of the underlying shares vesting on each anniversary of May 20, 2024, subject to the new employee's continued service relationship with Vera through the applicable vesting dates. The awards are subject to the terms and conditions of the Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.
2024年5月1日授予的每股股票期權的行使價等於每股42.32美元，即維拉在2024年5月1日的收盤交易價格。2024年5月7日授予的股票期權的每股行使價等於每股45.00美元，即維拉在2024年5月7日的收盤交易價格。每個股票期權將在四年內歸屬，25％的標的股票在適用的歸屬開始日期一週年之際歸屬，標的股份的餘額將在36個月內按月歸屬，視新員工在適用的歸屬日期之前與Vera的持續服務關係而定。每個限制性股票單位將在四年內歸屬，25％的標的股份將在2024年5月20日的每個週年紀念日歸屬，但要視新員工在適用的歸屬日期之前與Vera的持續服務關係而定。獎勵受激勵計劃的條款和條件以及涵蓋補助金的適用獎勵協議的條款和條件的約束。
About Vera
Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera's mission is to advance treatments that target the source of immunological diseases in order to change the standard of care for patients. Vera's lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger's disease, and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. Vera retains all global developmental and commercial rights to atacicept and MAU868. For more information, please visit .
關於維拉
Vera Therapeutics是一家處於臨床後期階段的生物技術公司，專注於開發嚴重免疫疾病的治療方法。Vera的使命是推進針對免疫疾病來源的治療方法，以改變患者的護理標準。Vera的主要候選產品是atacicept，這是一種融合蛋白，每週一次皮下注射自行給藥，可阻斷B細胞活化因子（BAFF）和促增殖配體（APRIL），刺激B細胞和漿細胞產生導致某些自身免疫性疾病的自身抗體，包括IgAN（也稱爲伯傑氏病）和狼瘡腎炎。此外，Vera正在評估其他疾病，在這些疾病中，通過阿他西普減少自身抗體可能被證明具有醫學用途。Vera 還在開發 MAU868，這是一種旨在中和 BK 病毒 (BKV) 感染的單克隆抗體。BKV 是一種多瘤病毒，可能在某些環境（例如腎臟移植）中造成毀滅性後果。Vera 保留 atacept 和 MAU868 的所有全球開發和商業權利。欲了解更多信息，請訪問。
For more information, please contact:
欲了解更多信息，請聯繫：
Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com
投資者聯繫人：
喬伊斯·阿萊爾
生命科學顧問
212-915-2569
jallaire@lifesciadvisors.com
Media Contact:
Mari Purpura
LifeSci Advisors
mpurpura@lifesciadvisors.com
媒體聯繫人：
Mari Purpura
生命科學顧問
mpurpura@lifesciadvisors.com
譯文內容由第三人軟體翻譯。